Pharmacological treatment of frontotemporal lobar degeneration: systematic review

Abstract

Objective: To identify the therapeutic options available for treatment of cognitive and behavioral symptoms in frontotemporal lobar degeneration. Method: Systematic review using the descriptors "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR "fronto-temporal dementia" OR "fronto-temporal degeneration" OR "Pick's disease" OR "Pick's atrophy" OR "semantic dementia" OR "progressive aphasia" AND "pharmacotherapy" OR "treatment" OR "efficacy" OR "effects" OR "management" was performed in the Medline and Lilacs databases. Selection criteria: Quality A -randomized clinical trials. Quality Bopen studies or reports of six or more cases. Quality C -reports of five or fewer cases. Two reviewers independently assessed the clinical studies. Information collected included diagnostic criteria used, sample size, duration, efficacy and tolerability measures used and results obtained. Results: From the 532 studies found, 29 complied with the inclusion criteria. All studies worked with a small sample, had short duration of treatment and used non-uniform measures in evaluating efficacy and tolerability. Studies showed disparate results with respect to behavior and cognition. Conclusion: There is still little, and poor, evidence available for treatment of frontotemporal lobar degeneration and studies with better methodological background are needed. Descriptors IntroductionThe clinical syndromes related to frontotemporal lobar degeneration (FTLD) are the second most common cause of pre-senile primary dementia. 1 A recent Brazilian epidemiological study found a dementia prevalence of 7.1% in individuals over

Recognizing Late Onset Frontotemporal Dementia with the DAPHNE scale: A case report

“…There is also consistent literature pointing to a worsening of behavioral symptoms in bvFTD with the use of cholinesterase inhibitors, as occurred in the case described. 20 …”

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

“…Regarding pharmacological approaches, a recent systematic review gathered information aiming to identify pharmacological interventions that could be used to treat the more troublesome behaviors in bvFTD. Trieu et al 78 Two reviews 82,83 published by Brazilian authors report that most studies have small sample sizes, short duration of treatment, and non-uniform measures while evaluating efficacy and tolerability.…”

“…Portugal et al 82 conducted a systematic review and reported better results for drugs with serotonergic action, such as selective serotonin reuptake inhibitors or SSRIs (paroxetine, citalopram, fluvoxamine) and trazodone to treat behavioral symptoms, but not cognition. Authors suggest that using SSRIs as the first-line treatment seems to be the best practice until better data on evidence-based strategies to rely upon are available.…”

Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

“…Duas revisões 82,83 publicadas por autores brasileiros relatam que a maioria dos estudos tem amostras pequenas, curta duração do tratamento e medidas não uniformes na avaliação da eficácia e tolerabilidade. Portugal et al 82 realizaram uma revisão sistemática e relataram melhores resultados para medicamentos com ação serotoninérgica, como inibidores seletivos da recaptação de serotonina-ISRS (paroxetina, citalopram, fluvoxamina) e trazodona para tratar sintomas comportamentais, mas não cognição. Os autores sugerem que o uso de ISRS como primeira alternativa parece ser a melhor prática de prescrição até que melhores dados sobre estratégias baseadas em evidências estejam disponíveis.…”

“…Two reviews 82 ),( 83 published by Brazilian authors report that most studies have small sample sizes, short duration of treatment, and non-uniform measures while evaluating efficacy and tolerability.…”